Suppr超能文献

无需准备的方法可在流感疫苗的工业化生产过程中快速筛选表面活性剂。

Preparation-free method can enable rapid surfactant screening during industrial processing of influenza vaccines.

机构信息

School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.

Viral Technology, MTech, Sanofi-Pasteur, Swiftwater, USA.

出版信息

Vaccine. 2019 Feb 14;37(8):1073-1079. doi: 10.1016/j.vaccine.2018.12.069. Epub 2019 Jan 23.

Abstract

Triton X-100 (TX-100) is the most common surfactant used to split viruses during the production of influenza split-virus vaccines. It is a mild surfactant not known to denature the viral proteins; this property makes TX-100 useful for maintaining antigen conformational structure, and, as an added benefit, for partially stabilizing vaccine formulations against protein aggregation. Despite its benefits, TX-100 needs to be filtered out after virus splitting has been achieved, due to its toxicity in large quantities. Accordingly, residual TX-100 presence in vaccine formulations has implications for both formulation stability and safety, necessitating both accurate screening during processing to guide decision-making about filtration repeats and accurate quantitation in the final product. Accurate HPLC-based methods are used successfully for the latter but their use for routine screening during processing is far from ideal because they often require extensive sample preparation and are fairly slow, complicated and costly. Here, "deconstruction" of UV-Vis absorption spectra into components corresponding to different absorbing "species" is demonstrated as a novel and viable method for routine TX-100 screening in vaccine samples from different industrial processing steps. This method is fairly accurate and, more importantly, preparation-free, rapid, simple/user-friendly and comparatively inexpensive. It is evaluated in depth in terms of applicability conditions, limitations and potential for high-throughput adaptation as well as generalization to other complex biopharmaceutical formulations.

摘要

曲拉通 X-100(TX-100)是在生产流感分病毒疫苗时拆分病毒最常用的表面活性剂。它是一种温和的表面活性剂,不会使病毒蛋白变性;这种特性使 TX-100 可用于保持抗原构象结构,并且作为额外的好处,可部分稳定疫苗制剂免受蛋白质聚集的影响。尽管有这些好处,但由于 TX-100 大量存在毒性,因此在实现病毒拆分后需要将其过滤掉。因此,疫苗制剂中残留的 TX-100 会对制剂的稳定性和安全性产生影响,这就需要在处理过程中进行准确的筛选,以指导过滤重复的决策,并在最终产品中进行准确的定量。成功地使用基于 HPLC 的准确方法进行后者,但由于它们通常需要广泛的样品制备并且相当缓慢、复杂和昂贵,因此其在处理过程中的常规筛选用途远非理想。在这里,将紫外可见吸收光谱“解构”成对应于不同吸收“物质”的成分,证明是一种用于从不同工业处理步骤的疫苗样品中进行常规 TX-100 筛选的新颖可行方法。该方法相当准确,更重要的是,无需进行样品制备,快速、简单、用户友好且相对便宜。它在适用性条件、限制以及适应高通量和推广到其他复杂生物制药制剂的潜力方面进行了深入评估。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验